Update shared on 14 Dec 2025
Fair value Decreased 3.89%Analysts have trimmed their price target on Healthpeak Properties to approximately $26.65 from about $27.73, reflecting slightly higher discount-rate assumptions and more modest revenue growth expectations, partially offset by improved profit margin and a lower projected future price to earnings multiple.
What's in the News
- Completed repurchase of 5,091,156 shares for approximately $94.17 million under the buyback program announced on July 25, 2024, representing about 0.73% of shares (Key Developments)
- No additional shares were repurchased between July 1, 2025 and September 30, 2025 under the existing buyback tranche, with total spending of $0 million in the period (Key Developments)
- Removed from the FTSE All-World Index (USD), which may affect index-linked ownership and trading volumes for the stock (Key Developments)
Valuation Changes
- Fair Value Estimate decreased slightly to approximately $26.65 from about $27.73.
- Discount Rate edged higher to roughly 8.21 percent from about 8.18 percent, indicating a modest increase in perceived risk or required return.
- Revenue Growth was reduced meaningfully to around 3.41 percent from about 4.88 percent, reflecting more conservative top line expectations.
- Net Profit Margin increased significantly to roughly 10.93 percent from about 7.21 percent, pointing to improved profitability assumptions.
- Future P/E was lowered markedly to about 68.0x from roughly 105.1x, suggesting a less aggressive valuation multiple on projected earnings.
Have other thoughts on Healthpeak Properties?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.